中西医结合治疗肺癌EGFR复合罕见突变1例

张葛; 刘水清清; 卢雯萍; 胡佳奇; 秦晓艳; 侯炜; 花宝金

doi:10.16025/j.1674-1307.2024.02.026

您当前的位置：

首页 >

文章列表页 >

中西医结合治疗肺癌EGFR复合罕见突变1例

医案医话 | 更新时间：2024-04-03

- 中西医结合治疗肺癌EGFR复合罕见突变1例
- A case of EGFR complex rare mutation in lung cancer treated with integrated Chinese and western medicine
- 北京中医药 2024年43卷第2期页码：220-222
- 作者机构：
  
  中国中医科学院广安门医院肿瘤科，北京 100053
- 作者简介：
  
  张葛，男，43岁，博士，副主任医师。研究方向：中西医结合防治恶性肿瘤。
  侯炜，E-mail： houwei1964@163.com
- 基金信息：
  
  兵团科技局“中医肿瘤治疗学科普资源开发”项目(2022CD018);中国中医科学院科技创新工程项目(CI2021B009);国家中医药管理局中医药创新团队及人才支持计划项目(ZYYCXTD-C-202205)
- DOI：10.16025/j.1674-1307.2024.02.026
  中图分类号：
- 纸质出版日期：2024-02-25，
  
  收稿日期：2023-05-11，
扫描看全文
张葛，刘水清清，卢雯萍，等.中西医结合治疗肺癌EGFR复合罕见突变1例［J］.北京中医药，2024，43（2）：220-222.

ZHANG Ge,LIU Shui-qingqing,LU Wen-ping,et al.A case of EGFR complex rare mutation in lung cancer treated with integrated Chinese and western medicine[J]. Beijing Journal of Traditional Chinese Medicine,2024,43(02):220-222.
张葛，刘水清清，卢雯萍，等.中西医结合治疗肺癌EGFR复合罕见突变1例［J］.北京中医药，2024，43（2）：220-222. DOI： 10.16025/j.1674-1307.2024.02.026.

ZHANG Ge,LIU Shui-qingqing,LU Wen-ping,et al.A case of EGFR complex rare mutation in lung cancer treated with integrated Chinese and western medicine[J]. Beijing Journal of Traditional Chinese Medicine,2024,43(02):220-222. DOI： 10.16025/j.1674-1307.2024.02.026.

摘要

Abstract

关键词

肺癌罕见突变表皮生长因子受体酪氨酸激酶抑制剂益气养阴活血化淤

Keywords

references

SIEGEL RL, MILLER KD, FUCHS HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022,72(1):7-33.

CORRIGAN AE, TAYLOR R, RALLIS KS. Next-generation sequencing of cancer genomes: lessons learned[J]. Future Oncol, 2021,17(31):4041-4044.

YAMADA Y, IMAI H, SUGIYAMA T, et al. Effectiveness and safety of EGFR-TKI rechallenge treatment in elderly patients with advanced non-small-cell lung cancer harboring drug-sensitive EGFR mutations[J]. Medicina (Kaunas), 2021,57(9):929.

PASSARO A, DE MARINIS F, TU HY, et al. Afatinib in EGFR TKI-Naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: a pooled analysis of three phase iiib studies[J]. Front Oncol, 2021,11:709877.

SCALVINI L, CASTELLI R, LA MONICA S, et al. Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry[J]. Biochem Pharmacol, 2021,190:114643.

ROCCO D, DELLA GRAVARA L, BATTILORO C, et al. The treatment of advanced lung adenocarcinoma with activating EGFR mutations[J]. Expert Opin Pharmacother, 2021,22(18):2475-2482.

ZHOU JY, LIU SY, WU YL. Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer[J]. Expert Opin Drug Saf, 2020,19(5):589-599.

MAJEED U, MANOCHAKIAN R, ZHAO Y, et al. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends[J]. J Hematol Oncol, 2021,14(1):108.

PASSARO A, MOK T, PETERS S, et al. Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations[J]. J Thorac Oncol, 2021,16(5):764-773.

KOBAYASHI Y, MITSUDOMI T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy[J]. Cancer Sci, 2016,107(9):1179-1186.

YANG JC, SEQUIST LV, GEATER SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6[J]. Lancet Oncol, 2015,16(7):830-838.

CHANG GC, LAM DC, TSAI CM, et al. Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations[J]. Int J Clin Oncol， 2021，26(5):841-850.

屠洪斌,董志毅,王少墨,等.原发性肺癌中医证型规律与化疗及靶向治疗的相关性研究[J].世界科学技术-中医药现代化,2014,16(9):1997-2001.

许海柱, 孙建立, 张璇. EGFR-TKI治疗后非小细胞肺癌中医证候研究[J]. 中国中西医结合杂志,2017,37(9):1050-1053.

HUANG J, MENG L, YANG B, et al. Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: a disproportionality analysis of FDA adverse event reporting system[J]. Sci Rep, 2020,10(1):4803.

余国芳, 林丽珠. 林丽珠辨治表皮生长因子受体抑制剂相关皮疹的经验探析[J]. 世界科学技术-中医药现代化,2009,11(5):758-763.

余勃, 许鹏. 加味沙参麦冬汤治疗肺癌患者EGFR-TKIs相关皮疹的临床研究[J]. 陕西中医药大学学报,2019,42(3):112-116.

BOWEN JM. Mechanisms of TKI-induced diarrhea in cancer patients[J]. Curr Opin Support Palliat Care, 2013,7(2):162-167.

胡洁,林丽珠,骆肖群,等.EGFR-TKI不良反应管理专家共识[J].中国肺癌杂志,2019,22(2):57-81.

黎钢, 曹岐新. 补脾止泻散治疗吉非替尼相关性腹泻的临床疗效观察[J]. 中国中医药科技,2021,28(4):654-655.

赵良辰,李陆振,袁锦辉,等.六君子汤加减联合吉非替尼片治疗晚期脾虚痰湿型非小细胞肺癌的临床研究[J].广州中医药大学学报,2021,38(2):250-256.

徐筱青, 时美伶, 燕晓茹,等. 肺癌靶向药物相关毒副反应辨治体会[J]. 中医杂志,2020,61(15):1357-1359.

薛江博. 扶正祛瘤方联合吉非替尼治疗非小细胞肺癌的疗效观察[J]. 中国社区医师,2021,37(25):87-88.

刘福栋,姜晓晨,花宝金,等.全国名中医朴炳奎“扶正培本”防治肺癌经验探析[J].北京中医药,2022,41(5):490-493.

花宝金,庞博,朴炳奎.中医药防治肺癌的优势与策略[J].北京中医药,2022,41(5):472-475.

更多指标>

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

活血化痰法防治肺癌EGFR-TKI靶向治疗耐药机制探讨

基于Transformer模型的人工智能肺癌方证结合预测系统构建

胡凯文分期论治肺癌经验

冷冻消融联合养肺方治疗对Lewis肺癌CD4⁺CD25⁺Foxp3⁺Treg的影响及机制

全国名中医朴炳奎“扶正培本”防治肺癌经验探析